Endo Withdraws Opana Painkiller From Market at FDA’s Request
Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily
Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily
Patients are 266 percent more likely to not pick up brand-name medications after requesting them at a pharmacy, compared to generic prescriptions, according to the Association for Accessible Medicine’s annual…
The FDA rejected Coherus Bioscience’s proposed biosimilar for Amgen’s Neulasta, Coherus announced. Source: Generic Line
A federal jury awarded GlaxoSmithKline $235 million in a suit against Teva, saying the generics manufacturer infringed on GSK’s patent for the cardiovascular drug Coreg when Teva marketed its generic…
The World Health Organization published its biennial update to its list of essential medicines, adding therapies for hepatitis C, HIV and leukemia, as well as new advice on combating antimicrobial…
The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA…
The Congressional Budget Office officially scored the Senate bill reauthorizing the FDA’s user fee agreements, saying it would add $740 million to the budget and a negligible amount to the…
<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-glaxosmithkline-abbvie.jpg" NAME"What Does It Take to Get Hired by GlaxoSmithKline and AbbVie" ALT"What Does It Take to Get Hired by GlaxoSmithKline and AbbVie"July 6, 2017By Mark Terry, BioSpace.com Breaking…
Life Sciences Jobs ... Source: BioSpace